Text Size

Staging and Outcome Depending on Surgical Treatment in Adenocarcinomas of the Oesophagogastric Junction

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Universitätsklinikum Hamburg-Eppendorf
ClinicalTrials.gov Identifier:
NCT01766986
First received: January 8, 2013
Last updated: January 15, 2013
Last verified: January 2013
History of Changes
  Purpose

Background: Owing to controversial staging and classification of adenocarcinoma of the oesophagogastric junction (AOG) before surgery, the choice of appropriate surgical approach remains problematic.

In a retrospective study, preoperative staging of AOG and the impact of preoperative misclassification on outcome were analysed. Methods: Data from patients with AOG were analysed from a prospectively collected database with regard to surgical treatment, preoperative and postoperative staging, and outcome.


Condition
Esophageal Carcinoma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Staging and Outcome Depending on Surgical Treatment in Adenocarcinomas of the Oesophagogastric Junction

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Universitätsklinikum Hamburg-Eppendorf:

Primary Outcome Measures:
  • Overall survival [ Time Frame: 60 months ] [ Designated as safety issue: Yes ]

Enrollment: 130
Study Start Date: January 2008
Study Completion Date: January 2012
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

One-hundred and thirty patients with Siewert types I and II AOG who did not have neoadjuvant treatment were included in the study

Criteria

Inclusion Criteria:

  • One-hundred and thirty patients with Siewert types I and II AOG who did not have neoadjuvant treatment were included in the study

Exclusion Criteria:

  • AOG type III
  • no surgical resection
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01766986

Sponsors and Collaborators
Universitätsklinikum Hamburg-Eppendorf
Investigators
Study Chair: Jakob R Izbicki, MD. University Hospital Hamburg-Eppendof, Hamburg, Germany
  More Information

No publications provided

Responsible Party: Universitätsklinikum Hamburg-Eppendorf
ClinicalTrials.gov Identifier: NCT01766986     History of Changes
Other Study ID Numbers: AEGII-2012
Study First Received: January 8, 2013
Last Updated: January 15, 2013
Health Authority: Germany: Ethics Commission

Additional relevant MeSH terms:
Adenocarcinoma
Adenocarcinoma, Mucinous
Carcinoma
Esophageal Diseases
Esophageal Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
 Neoplasms, Cystic, Mucinous, and Serous
Gastrointestinal Diseases
Digestive System Diseases
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms

ClinicalTrials.gov processed this record on May 21, 2013